Published Online:16 Jun 2010https://doi.org/10.2217/bmm.10.60
Abstract
Acute myocardial infarction (AMI) is the major cause of death worldwide. Cardiac troponins (cTns) are structural proteins, unique to the heart, that currently form the cornerstone of the AMI diagnosis. The major limitation of standard cTn assays is a sensitivity deficit at presentation caused by a delayed increase of circulating levels. Recent multicenter studies have demonstrated that novel, more sensitive and precise cTn assays improve the early diagnosis of AMI. cTn has to be interpreted as a quantitative variable. The term ‘troponin positive’ should, therefore, be avoided. ‘Detectable’ levels will become the norm and have to be clearly differentiated from ‘elevated’ levels. The differential diagnosis of a small amount of myocardial injury and, therefore, mild elevation of cTn is broad, and includes acute and chronic disorders. The differential diagnosis of a large amount of myocardial injury and, therefore, substantial elevation of cTn is much smaller and largely restricted to AMI, myocarditis and takotsubo cardiomyopathy. The aim of this article is to guide clinicians in the use of sensitive cTn.
Bibliography
- 1 Nawar Ew, Niska Rw, Xu J: National hospital ambulatory medical care survey: 2005 emergency department summary. Adv. Data386,1–32 (2007).
- 2 Anderson JL, Adams CD, Antman EM et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation116(7),e148–e304 (2007).
- 3 Bassand JP, Hamm CW, Ardissino D et al.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J.28(13),1598–1660 (2007).
- 4 Thygesen K, Alpert JS, White HD et al.: Universal definition of myocardial infarction. Circulation116(22),2634–2653 (2007).
- 5 Pope JH, Aufderheide TP, Ruthazer R et al.: Missed diagnoses of acute cardiac ischemia in the emergency department. N. Engl. J. Med.342(16),1163–1170 (2000).
- 6 Wang K, Asinger RW, Marriott HJ: ST-segment elevation in conditions other than acute myocardial infarction. N. Engl. J. Med.349(22),2128–2135 (2003).
- 7 Morrow DA, Cannon CP, Rifai N et al.: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA286(19),2405–2412 (2001).
- 8 Morrow DA, Antman EM, Tanasijevic M et al.: Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J. Am. Coll. Cardiol.36(6),1812–1817 (2000).
- 9 Mueller C, Neumann FJ, Perruchoud AP, Zeller T, Buettner HJ: Prognostic value of quantitative troponin T measurements in unstable angina/non-ST-segment elevation acute myocardial infarction treated early and predominantly with percutaneous coronary intervention. Am. J. Med.117(12),897–902 (2004).
- 10 Hochholzer W, Buettner HJ, Trenk D et al.: New definition of myocardial infarction: impact on long-term mortality. Am. J. Med.121(5),399–405 (2008).
- 11 Hamm CW, Heeschen C, Goldmann B et al.: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. C7e3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) study investigators. N. Engl. J. Med.340(21),1623–1629 (1999).
- 12 Kastrati A, Mehilli J, Neumann FJ et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA295(13),1531–1538 (2006).
- 13 Eggers KM, Oldgren J, Nordenskjold A, Lindahl B: Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am. Heart J.148(4),574–581 (2004).
- 14 Mccann CJ, Glover BM, Menown IB et al.: Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur. Heart J.29(23),2843–2850 (2008).
- 15 Macrae AR, Kavsak PA, Lustig V et al.: Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. Clin. Chem.52(5),812–818 (2006).
- 16 Forberg JL, Henriksen LS, Edenbrandt L, Ekelund U: Direct hospital costs of chest pain patients attending the emergency department: a retrospective study. BMC Emerg. Med.6,6 (2006).
- 17 Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH: National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Circulation115(13),e352–e355 (2007).
- 18 Apple FS, Wu AH, Jaffe AS: European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am. Heart J.144(6),981–986 (2002).
- 19 Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, Van Dieijen-Visser M: Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin. Chem.55(1),101–108 (2008).
- 20 Melanson SE, Morrow DA, Jarolim P: Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am. J. Clin. Pathol.128(2),282–286 (2007).
- 21 Apple FS, Smith SW, Pearce LA, Ler R, Murakami MM: Use of the centaur TnI-Ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin. Chem.54(4),723–728 (2008).
- 22 Hamm CW: Acute coronary syndromes: the diagnostic role of troponins. Thromb. Res.103,S63–S69 (2001).
- 23 Jaffe AS: Chasing troponin: how low can you go if you can see the rise? J. Am. Coll. Cardiol.48(9),1763–1764 (2006).
- 24 Katus HA, Looser S, Hallermayer K et al.: Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin. Chem.38(3),386–393 (1992).
- 25 Ricchiuti V, Apple FS: RNA expression of cardiac troponin T isoforms in diseased human skeletal muscle. Clin. Chem.45(12),2129–2135 (1999).
- 26 Ricchiuti V, Voss EM, Ney A, Odland M, Anderson PA, Apple FS: Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by boehringer mannheim. Clin. Chem.44(9),1919–1924 (1998).
- 27 Remppis A, Scheffold T, Greten J et al.: Intracellular compartmentation of troponin T: release kinetics after global ischemia and calcium paradox in the isolated perfused rat heart. J. Mol. Cell. Cardiol.27(2),793–803 (1995).
- 28 Apple FS: A new season for cardiac troponin assays: it’s time to keep a scorecard. Clin. Chem.55(7),1303–1306 (2009).
- 29 Reichlin T, Hochholzer W, Bassetti S et al.: Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N. Engl. J. Med.361(9),858–867 (2009).
- 30 Keller T, Zeller T, Peetz D et al.: Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N. Engl. J. Med.361(9),868–877 (2009).
- 31 Omland T, De Lemos JA, Sabatine MS et al.: A sensitive cardiac troponin T assay in stable coronary artery disease. N. Engl. J. Med.361(26),2538–2547 (2009).
- 32 Kelley WE, Januzzi JL, Christenson RH: Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin. Chem.55(12),2098–2112 (2009).
- 33 Morrow DA, Cannon CP, Jesse RL et al.: National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation115(13),e356–e375 (2007).
